CUREator
Overview
CUREator is an Australian national biotechnology incubator, delivered by Brandon BioCatalyst, that provides non-dilutive grant funding and support to early-stage biomedical research and innovations to bridge the gap between discovery and investment readiness.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| GPN Vaccines | May 2024 | Grant | Co-investor |
| Respirion Pharmaceuticals | May 2024 | Grant | Co-investor |
| Redenlab | Sep 2025 | Grant | Co-investor |
| RAGE Biotech | Sep 2025 | Grant | Co-investor |
| xCystence Bio | Sep 2025 | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is CUREator based?
CUREator is headquartered in Melbourne, Australia.
When was CUREator founded?
CUREator was founded in 2021.
How many portfolio companies does CUREator have?
CUREator has 17 portfolio companies in Caplight's dataset.
What are some companies in CUREator's portfolio?
Portfolio companies visible on Caplight include GPN Vaccines, Respirion Pharmaceuticals, Redenlab, RAGE Biotech, xCystence Bio.
What was CUREator's most recent investment shown here?
CUREator's most recent investment in this portfolio sample was in Redenlab in 2025.
What sectors does CUREator focus on?
CUREator focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software.
What company stages does CUREator focus on?
Stage focus information for CUREator is not publicly available.
What is CUREator's AUM?
CUREator's assets under management are estimated between $96.0M and $96.0M.